Clinical Trials
4
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:3
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Not Applicable
1 (25.0%)Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer
Not Applicable
Not yet recruiting
- Conditions
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Interventions
- Drug: HS-20093 in combination with Adebrelimab
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Shanghai Hansoh Biomedical Co., Ltd
- Target Recruit Count
- 50
- Registration Number
- NCT07063407
ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumor
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Shanghai Hansoh Biomedical Co., Ltd
- Target Recruit Count
- 177
- Registration Number
- NCT05276609
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of HS-20089 in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: HS-20089 (Phase Ia：Dose escalation )
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Shanghai Hansoh Biomedical Co., Ltd
- Target Recruit Count
- 177
- Registration Number
- NCT05263479
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Comparing of the Pharmacokinetic, Safety and Immunogenicity of HS-20090-2 Injection and Prolia® in Healthy Adults
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Shanghai Hansoh Biomedical Co., Ltd
- Target Recruit Count
- 174
- Registration Number
- NCT04940845
- Locations
- 🇨🇳
Huazhong University of Science and Technoogy, Wuhan, Hubei, China
News
No news found